CSF3 and neutropenia: This may be explained by advances in supportive care, including routine use of mould‐active prophylaxis6 as well as routine use of early G‐CSF; the latter resulting in an apparent shorter duration of neutropenia in our cohort relative to other series, such as the RADIUS‐X expanded access midostaurin program (median 22 vs 26 days).26